Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)
Abstract Muscle wasting in cancer is a common and often occult condition that can occur prior to overt signs of…